• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国妇科癌症学会/英国妇科病理学会共识:英国卵巢癌 1/2 变体种系和肿瘤检测。

British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for 1/2 variants in ovarian cancer in the United Kingdom.

机构信息

Gynaecological Oncology, Pan-Birmingham Gynaecological Cancer Centre, Birmingham, UK

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

出版信息

Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19.

DOI:10.1136/ijgc-2020-002112
PMID:33468564
Abstract

The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.

摘要

英国妇科癌症学会和英国妇科病理学家协会成立了一个多学科共识小组,成员包括妇科肿瘤学、肿瘤内科、遗传学和实验室科学方面的专家,以及临床护士专家,以确定在常规临床实践中对卵巢癌患者进行种系和肿瘤检测的最佳途径。特别是,该小组探讨了同意模式、病理学实验室确定的质量标准,以及来自开创性癌症中心的经验和数据。该小组还与卵巢癌慈善机构的代表联系,以确定对实施具有重要意义的患者观点。这些共识小组审议的建议在本手稿中提出。

相似文献

1
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for 1/2 variants in ovarian cancer in the United Kingdom.英国妇科癌症学会/英国妇科病理学会共识:英国卵巢癌 1/2 变体种系和肿瘤检测。
Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19.
2
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.英国妇科癌症学会/英国妇科病理学会联合共识:在英国进行上皮性卵巢癌的基因检测。
Int J Gynecol Cancer. 2024 Sep 2;34(9):1334-1343. doi: 10.1136/ijgc-2024-005756.
3
Prevalence of germline pathogenic variants in sequential epithelial ovarian cancer cases.连续上皮性卵巢癌病例中种系致病性变异的流行率。
J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.
4
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.上皮性卵巢癌的未选择多基因胚系和体细胞遗传检测的成本效益。
J Natl Compr Canc Netw. 2024 Apr 18;22(2 D):e237331. doi: 10.6004/jnccn.2023.7331.
5
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.英国卵巢癌女性中胚系BRCA1和BRCA2检测的成本效益评估。
Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
6
Uptake of testing for germline mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.西澳大利亚州非黏液性上皮性卵巢癌患者种系突变检测的应用:不同遗传咨询方法的比较。
Int J Gynecol Cancer. 2019 Jul;29(6):1038-1042. doi: 10.1136/ijgc-2019-000389. Epub 2019 May 17.
7
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.在英格兰西北部将胚系 BRCA1/2 检测纳入非黏液性上皮性卵巢癌的常规检测。
Eur J Hum Genet. 2020 Nov;28(11):1541-1547. doi: 10.1038/s41431-020-0692-y. Epub 2020 Jul 10.
8
Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.海湾地区卵巢癌患者中 BRCA1 和 BRCA2 致病性序列变异的流行情况:PREDICT 研究。
BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.
9
Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.土耳其上皮性卵巢癌女性种系 BRCA1/2 突变的频率及其与临床病理特征的关系。
Asia Pac J Clin Oncol. 2022 Feb;18(1):84-92. doi: 10.1111/ajco.13520. Epub 2021 Feb 25.
10
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.韩国一家机构十余年经验:上皮性腹膜癌、卵巢癌和输卵管癌的胚系和体细胞BRCA1/2基因突变状态及临床结局
Cancer Res Treat. 2020 Oct;52(4):1229-1241. doi: 10.4143/crt.2020.557. Epub 2020 Jul 27.

引用本文的文献

1
Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer.种系、体细胞和循环肿瘤DNA检测在成年癌症患者中的应用价值
Cancer Med. 2025 Aug;14(15):e71080. doi: 10.1002/cam4.71080.
2
Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project.促进卵巢癌基因检测的公平性:分子卵巢癌检测改善示范(DEMO)项目
BMJ Open Qual. 2025 Feb 25;14(Suppl 1):e002720. doi: 10.1136/bmjoq-2023-002720.
3
Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.
医生对新诊断晚期卵巢癌患者管理中基因生物标志物检测的知识、应用及认知:一项国际医生调查
Future Oncol. 2025 Feb;21(4):437-445. doi: 10.1080/14796694.2025.2449782. Epub 2025 Jan 15.
4
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.高级别卵巢癌患者的同源重组缺陷检测:影响检测成功的因素
Future Oncol. 2025 Feb;21(3):341-347. doi: 10.1080/14796694.2024.2433412. Epub 2024 Nov 29.
5
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).英国晚期高级别上皮性卵巢癌的当前管理实践:OC-NOW调查(2023年)
Future Oncol. 2025 Jan;21(1):95-103. doi: 10.1080/14796694.2024.2424153. Epub 2024 Nov 25.
6
Screening and prevention of ovarian cancer.卵巢癌的筛查与预防。
Med J Aust. 2024 Mar 18;220(5):264-274. doi: 10.5694/mja2.52227. Epub 2024 Feb 14.
7
Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon.黎巴嫩铂敏感型高级别浆液性上皮性卵巢癌管理共识
Gynecol Oncol Rep. 2023 Apr 23;47:101186. doi: 10.1016/j.gore.2023.101186. eCollection 2023 Jun.
8
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer.英国妇科癌症协会关于基于证据的、源自人群数据的卵巢癌质量绩效指标的建议。
Cancers (Basel). 2023 Jan 4;15(2):337. doi: 10.3390/cancers15020337.
9
Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.医护人员对在卵巢癌患者中实施肿瘤通用 DNA 检测的看法:多学科焦点小组。
Fam Cancer. 2023 Jan;22(1):1-11. doi: 10.1007/s10689-022-00294-0. Epub 2022 May 16.
10
Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing.使用下一代测序技术检测卵巢癌患者中胚系和体细胞致病性/可能致病性变异以及其他易感基因的真实世界数据。
Cancers (Basel). 2022 Mar 10;14(6):1434. doi: 10.3390/cancers14061434.